Recommended

Teva close to API business sale
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

HER2-positive metastatic breast cancer treatment granted Priority Review

180
SHARES

Priority Review has been granted for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of HER2-positive metastatic breast cancer.

The US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for review and granted Priority Review for [fam-] trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody drug conjugate (ADC) and potential new medicine for the treatment of HER2-positive metastatic breast cancer.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The Prescription Drug User Fee Act (PDUFA) date for the treatment is set for the second quarter of 2020, AstraZeneca and Daiichi Sankyo Company Ltd, which produce the drug, have announced.

“[Fam-] trastuzumab deruxtecan has the potential to transform the treatment landscape for patients with HER2-positive metastatic breast cancer who have limited treatment options today,” said José Baselga, Executive Vice President, Oncology R&D, AstraZeneca. “This Priority Review draws on the strength and the consistency of results seen in the Phase I and Phase II trials and is a critical step on the journey to deliver this potential new medicine to patients.”

We believe [fam-] trastuzumab deruxtecan has the potential to redefine the treatment of patients with HER2-positive metastatic breast cancer”

The BLA is based on the combination of data from the Phase I trial and the pivotal Phase II DESTINY-Breast01 trial. The response rate observed in DESTINY-Breast01, as assessed by an independent review committee, validated the results observed in the Phase I trial.

“We are pleased that the FDA has accepted the application and granted Priority Review, as we believe [fam-] trastuzumab deruxtecan has the potential to redefine the treatment of patients with HER2-positive metastatic breast cancer,” added Antoine Yver, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo. “Following the recent regulatory submission in Japan, we look forward to working closely with regulatory authorities to bring [fam-] trastuzumab deruxtecan to patients in the US and Japan as soon as possible.”

Share via
Share via